Global Glaucoma Market Examined & Forecast by Koncept Analytics in Its Cutting-Edge Report Recently Uploaded at MarketPublishers.com
05 Jun 2017 • by Natalie Aster
LONDON – Although, glaucoma can’t be cured completely, the progression of this disease can be controlled with the use of available treatment options, namely invasive surgery, laser and drugs.
Spurred by a range of factors including expanding prevalence of diabetes, increasing geriatric population, rising disposable income, escalating healthcare expenditures and enhancing number of obese people, the world’s glaucoma market is poised to grow in the coming years. Some of the notable market trends comprise development and introduction of new drugs, devices and IOP-focused therapies.
However, growth in the glaucoma market could be hampered by certain factors, for example, high treatment costs, hasty drug approval processes and severe side effects.
Pfizer, Merck & Co., Allergan Plc. and Novartis AG are the dominant players in the worldwide glaucoma market.
The cutting-edge report “Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)” prepared by Koncept Analytics highlights the histrocial and current development of the world’s glaucoma market, with a focus on the US market. It covers the top trends, examines the key growth drivers and restraints, pinpoints the major challenges and opportunities. this research study covers the competitive landscape and gives profiles of the leading player with details on their strategies, recent initiative and financial performance. Future forecasts through 2021 are at hand as well.
Follow to the Koncept Analytics page to find a full collection of the publisher’s research reports.